Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

This study has been completed.

Study NCT00077363 Information provided by Eastern Cooperative Oncology Group

First Received: February 10, 2004 Last Updated: January 27, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)

Publications:

Wang M, Gradishar WJ, Sparano JA, et al.: A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103. [Abstract] J Clin Oncol 25 (Suppl 18): A-1036, 2007.